November 12, 2013
1 min read

Alimera reports net loss of $1.1 million for third quarter

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Alimera has reported a net loss of $1.1 million attributable to common shareholders for the third quarter of 2013, compared to a $5.4 million net loss reported in the third quarter of 2012, according to a company press release.

The net earnings for the third quarter of 2013 did, however, benefit from a decrease in the fair value of Alimera's derivative warrant liability, which resulted in non-cash income of approximately $6.2 million and a non-cash unrealized foreign currency gain of $508,000, the release said.

As of Sept. 30, 2013, Alimera had cash and cash equivalents of $23.1 million, compared to $49.6 million as of Dec. 31, 2012, according to the release.

Total revenue from Iluvien, comprised of sales in Germany and the U.K. in the third quarter of 2013, was $758,000, up 323% from last quarter’s posted revenue of $179,000.

In addition to its current activity in Germany and the United Kingdom, Alimera anticipates a commercial launch of Iluvien in France in 2014, the release said.

"During the third quarter, our commercial focus on Europe continued to grow as we increased revenue over 300% and expanded the number of physicians implanting Iluvien in their patients in Germany and the United Kingdom," Dan Myers, Alimera's president and CEO, said in the release.